FDA Akeega

FDA Approves J&J Combo Drug for Prostate Cancers With Certain Genetic Signature

Johnson & Johnson’s Akeega is approved for treating advanced prostate cancer with a BRCA mutation. The drug, which interferes with a way cancer cells repair themselves, will compete against recently approved drugs from Pfizer and partners AstraZeneca and Merck.

By Frank Vinluan

Physicians

OmniLife Health’s Clinical Workflow Solution Focuses on Complex Care

OmniLife Health's initial focus with its complex care coordination platform is organ transplant care.

Health Tech

HealthBook+ CEO Shares Vision for How People Can Own Their Health by Leveraging Data and AI

HealthBook+ provides a way for individuals to aggregate and use their personal health information safely and securely to power AI engines that direct people to their next best health action. Importantly, it also gives employers predictive insights to help them provide the most relevant benefits for their employees.